Associated Papers
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
41556616 (PubMed )
Supplement: PRO-35-e70422-s002.xlsx › Table_S1
DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome.
Todoerti K et al.
Haematologica, 2022
33951891 (PubMed )
Supplement: 2021_278342_TODOERTI_SUPPL.pdf
Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma.
Manzoni M et al.
Cancers, 2020
32456143 (PubMed )
Supplement: cancers-12-01332-s001.pdf
The RNA Exosome and Human Disease.
Fasken MB et al.
Methods in Molecular Biology (clifton, N.j.), 2020
Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing.
Ruiz-Heredia Y et al.
Haematologica, 2018
A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias.
Lionetti M et al.
Oncotarget, 2015
Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns.
Cifola I et al.
Oncotarget, 2015
26046463 (PubMed )
Supplement: oncotarget-06-17543-s001.pdf
Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P).
Kortüm KM et al.
Annals of Hematology, 2015
Select a paper to view details